Phase 2 trial of utility and safety for bevacizumab in combination with adjuvant chemotherapy in cervical cancer

Phase 2 trial of utility and safety for bevacizumab in combination with adjuvant chemotherapy in cervical cancer - Trial of adjuvant chemotherapy with bevacizumab in cervical cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026986

Enrollment

Registered

2017-05-01

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

paclitaxel(175mg/m2) + carboplatin(AUC5) + bevacizumab(15mg/kg) for 6 months

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)Diagnosis with cervical cancer. 2)PS 0 or 1 3)Consent from the patient. 4)Pathological examination recognized risk of recurrence.

Exclusion criteria

Exclusion criteria: 1)Patients have severe fever. 2)Patients have a hystory acute myocardial infarction. 3)Patients have ileus symptom. 4)Patients have poor control of DM and HT and VTE.

Design outcomes

Primary

Measure	Time frame
Disease-free survival	—

Secondary

Measure	Time frame
Side effect	—

Countries

Japan

Contacts

Public ContactKeisuke Ashihara

Osaka medical college Obstetrics and gynecology

gyn140@osaka-med.ac.jp072-863-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026